NextRNA Therapeutics is developing small molecule therapeutics that work by targeting long non-coding RNAs. The majority of RNAs found in cells do not make proteins, instead they are non-coding and play various regulatory roles within cells. Long non-coding RNAs (lncRNAs) can function by interacting with various proteins, RNA and DNA, with their dysregulation observed in various diseases. NextRNA is using their drug discovery engine to identify, validate and selectively disrupt disease-relevant lncRNAs with small molecules.

NextRNA Therapeutics

Women in Biotech: NextRNA CEO Dominique Verhelle - GBH News

Bayer partners with NextRNA to develop lncRNA-targeting cancer therapies - Pharmaceutical Business Review

Bayer teams up with lncRNA-focused NextRNA in $547m deal - Pharmaceutical Technology

Bayer and NextRNA: One partnership, two oncology programs - BioXconomy

Bayer and NextRNA Sign $500M+ IncRNA Oncology Deal - Inside Precision Medicine

Long non-coding RNAs: what’s behind the growing “dark genome” buzz? - Labiotech.eu


								
																			September 26 2024																	
								NextRNA Therapeutics Expands Executive Team with Appointment of  Jesse Smith, PhD as Chief Scientific Officer
								More
							


								
																			October 23 2024																	
								The ‘Junk’ Genome May Actually Unlock The Next Cancer Treatment
																	
										Forbes									
																More
							


								June 21 2023
																	The Long and Short of It:  Exploring the Therapeutic Potential of lncRNAs
																Q&A with Susan Carpenter, PhD
																	Associate Professor of Molecular, Cell & Developmental Biology at UC Santa Cruz
																									Scientific Advisor, NextRNA Therapeutics
																More
							

Our CEO Dominique Verhelle participated in a panel discussion yesterday focused on non-coding RNA (ncRNA) and epigenetics at the #DarkGenomeSymposium in NYC. Dominique shared NextRNA's therapeutic approach, which is centered on inhibiting the function of long non-coding RNAs (lncRNAs) by disrupting the interaction between lncRNAs and RNA-binding proteins with small molecules. 

We're excited to be an industry pioneer in the broad, emerging dark genome field, and a leader in interrogating and translating the potential of lncRNAs to address significant unmet needs in oncology and neuroscience.   

#lncRNA #ncRNA #RNA #darkgenome #DGS2024

 NextRNA Therapeutics on LinkedIn: #bio2024 #rna #ncrna #lncrna #bio24 #cancer #oncology… 

 NextRNA Therapeutics Names Dominique Verhelle as CEO and Expands Leadership Team 

Our Co-Founder & CEO, Dominique Verhelle, will give a corporate presentation on Monday, Sep. 30th at 1:30 pm ET at Chardan’s 8th Annual Genetic Medicines Conference in NYC. 

There is increasing evidence that lncRNAs are implicated in the pathogenesis of a broad spectrum of diseases. With our unique platform and capabilities, NextRNA is well positioned to discover new lncRNA targets and develop transformative small molecule medicines for patients.

We look forward to discussing our progress as a leader in the rapidly emerging lncRNA space at #ChardanGMConf!

#RNA #smallmolecule #lncRNA #darkgenome


								
																			August 28 2024																	
								Bayer signs $547 million pact with NextRNA in oncology push
																	
										Bloomberg									
																More
							

Bayer and NextRNA Therapeutics enter oncology partnership worth $547m - PMLiVE


								
																			September 10 2024																	
								Long non-coding RNAs: what’s behind the growing “dark genome” buzz?
																	
										Labiotech.eu									
																More
							

We’re excited to announce that Charles Kunsch has been appointed to our Board of Directors! 

Read the press release: https://bit.ly/4fkC2Jj

Currently a Venture Partner at Dreavent Capital and previously Managing Director of AbbVie Ventures, Dr. Kunsch brings to NextRNA’s board more than 30 years of leadership in drug R&D, business development, and life science venture investing.

Dr. Kunsch’s appointment caps off a year of important milestones for NextRNA Therapeutics as we continue to solidify our leadership in the emerging lncRNA space. We look forward to many more milestones in the year ahead!

#lncRNA #ncRNA #RNAmedicines


We’re excited to announce the appointment of Jesse Smith as NextRNA’s Chief Scientific Officer! With his deep expertise in pioneering first-in-class targeted small molecule therapies, Dr. Smith is ideally suited to lead our scientific organization. 

At NextRNA we are focused on inhibiting the function of disease-driving lncRNAs with small molecules. With our unique platform and capabilities, we have the potential to address multiple high unmet diseases and deliver transformative medicines for patients.

Welcome to the NextRNA team, Jesse!

Read press release: https://bit.ly/4eiFGUD

#RNA #smallmolecule #drugdiscovery #drugdevelopment #lncRNA #darkgenome


								
																			August 28 2024																	
								Bayer partners with RNA drugmaker to develop new cancer therapies
																	
										BioPharma Dive									
																More
							


								
																			December 08 2022																	
								NextRNA Therapeutics to Participate in Upcoming 5th Annual RNA-Targeted Drug Discovery Summit
								More
							

Bayer partners with RNA drugmaker to develop new cancer therapies - BioPharma Dive

Our team recently set sail for an unforgettable team-building adventure in Newport, RI, where we raced 12-meter America's Cup sailboats! It was not only an amazing experience navigating the open waters together but also a celebration of our new strategic collaboration with Bayer and warm welcome to our newest employees.

Although we didn't have the expected wind for the race, the calm seas gave us the perfect chance to unwind, connect, and enjoy the day. As we worked together to adjust the sails and navigate the course, we truly embodied the essence of our company: teamwork, resilience, and a shared determination to always move forward.

Here's to welcoming new faces, embracing fresh challenges, and celebrating many more victories ahead—both on and off the water!

#TeamBuilding #NewportRI #AmericasCup #LeadershipInAction #Sailing #Teamwork #CompanyCulture

Boston biotech signs deal with Bayer worth up to $547M - The Business Journals

 NextRNA Therapeutics’ Post 

Bayer partners with RNA startup launched out of Dana-Farber - Endpoints News

 Jeff Coller on LinkedIn: Check it out! 

Bayer, NextRNA to Develop Therapeutics Targeting Oncology - Yahoo Finance


								June 06 2023
																	The Long and Short of It:  Exploring the Therapeutic Potential of lncRNAs
																Q&A with John Mattick, PhD
																	Professor of RNA Biology at UNSW Sydney
																									Scientific Advisor, NextRNA Therapeutics
																More
							


								
																			September 26 2023																	
								NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD
								More
							

Bayer signs $547 million pact with Boston-based NextRNA in oncology push - The Boston Globe

 NextRNA Therapeutics Appoints Charles Kunsch, Ph.D. to Board of Directors 

NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD - Business Wire

A new biotech out of Dana-Farber wants to join the long non-coding RNA party, with help from Bob Langer - Endpoints News

NextRNA Therapeutics Appoints Seasoned Industry Leader Charles Kunsch, Ph.D. to Board of Directors - Business Wire

Bayer pens $547M biobucks pact with biotech pushing the boundaries of noncoding RNA - Fierce Biotech

Bayer inks deal with NextRNA on IncRNA-driven diseases - The Pharma Letter

NextRNA Launches with $56 Million in Funding to Bring Transformative Non-Coding RNA-Directed Medicines to Patients - Business Wire

 NextRNA Therapeutics Raises $56M in Seed and Series A Funding 


								
																			August 28 2024																	
								Bayer pens $547M biobucks pact with biotech pushing the boundaries of noncoding RNA FierceBiotech
																	
										FierceBiotech									
																More
							

I look forward to participating in this partnership-focused panel at the Longwood Healthcare Leaders Boston CEO forum next week to discuss how NextRNA and Bayer's collaboration is reflective of each organization's respective mission and strategy, and how our two organizations are working to shape a true collaboration, where each party has important contributions to ensure its success.

At NextRNA, we believe in the power of community and the importance of supporting and empowering women. Recently, a group of our amazing employees had the honor of volunteering at Rosie's Place, a sanctuary for poor and homeless women in Boston. Together, we served meals, provided support, and contributed to an incredible organization that uplifts women every day.

💪 When we empower women, we strengthen our community and fuel a brighter future for everyone. Thank you, Rosie’s Place, for the vital work you do, and thank you to our volunteers for making an impact!

#EmpoweringWomen #VolunteerWork #Community #CompanyValues #RosiesPlace #WomenSupportingWomen #GivingBack


								
																			September 22 2022																	
								NextRNA Therapeutics to Participate in Upcoming BioPharm America and Chardan’s 6th Annual Genetic Medicines Conference
								More
							

Lilly taps RNA biotech for $1 billion weight-loss collaboration - Chemical & Engineering News

Fenwick Represents NextRNA Therapeutics in Strategic Collaboration with Bayer - Fenwick & West LLP

Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) in Oncology - Business Wire

Bayer Signs $547 Million Pact With NextRNA in Oncology Push - Bloomberg


								
																			September 04 2024																	
								Bayer and NextRNA sign $500M+ lncRNA oncology deal
																	
										Inside Precision Medicine									
																More
							

 Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) in Oncology 


              Women in Biotech
            


								
																			August 11 2022																	
								NextRNA Therapeutics names Dominique Verhelle as CEO and expands leadership team
								More
							


              The ‘Junk’ Genome May Actually Unlock The Next Cancer Treatment
            

Our Co-Founder and CEO, Dominique Verhelle, will participate in a panel on Oct. 28 at 4:10pm at the Longwood Healthcare Leaders Boston CEO forum, titled "Aligning Priorities for the Partnership." As part of the discussion, Dominique will share her insights on structuring innovation-driving partnerships to advance first-in-class cancer therapies through the lens of NextRNA's recently announced strategic collaboration with Bayer to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology. 

For more information and to register visit: https://lnkd.in/eehfZ2xB

#longwoodhealthcareleaders  


								
																			December 12 2024																	
								NextRNA Therapeutics Appoints Seasoned Industry Leader Charles Kunsch, Ph.D. to Board of Directors
								More
							

 NextRNA Therapeutics Expands Executive Team with Appointment of Jesse Smith, PhD as Chief Scientific Officer 

NextRNA Therapeutics

Business:

About: